431 related articles for article (PubMed ID: 28438129)
41. Persistence of Mycobacterium leprae in the peripheral nerve as compared to the skin of multidrug-treated leprosy patients.
Shetty VP; Suchitra K; Uplekar MW; Antia NH
Lepr Rev; 1992 Dec; 63(4):329-36. PubMed ID: 1479872
[TBL] [Abstract][Full Text] [Related]
42. A follow up of T-cell subsets and of anti-M. leprae antibody titer as measured by the FLA-ABS test in Melanesian leprosy patients under polychemotherapy.
Garraud O; Ribierre O; Bach MA
Int J Lepr Other Mycobact Dis; 1986 Mar; 54(1):38-45. PubMed ID: 2940306
[TBL] [Abstract][Full Text] [Related]
43. Leprosy in Nonimmigrant Canadian Man without Travel outside North America, 2014.
Bonnar PE; Cunningham NP; Boggild AK; Walsh NM; Sharma R; Davis IRC
Emerg Infect Dis; 2018 Jan; 24(1):165-166. PubMed ID: 29260666
[TBL] [Abstract][Full Text] [Related]
44. Relapse as histoid leprosy after receiving multidrug therapy (MDT); a report of three cases.
Shaw IN; Ebenezer G; Rao GS; Natrajan MM; Balasundaram B
Int J Lepr Other Mycobact Dis; 2000 Sep; 68(3):272-6. PubMed ID: 11221089
[TBL] [Abstract][Full Text] [Related]
45. Quantitative real-time PCR analysis of Mycobacterium leprae DNA and mRNA in human biopsy material from leprosy and reactional cases.
Lini N; Shankernarayan NP; Dharmalingam K
J Med Microbiol; 2009 Jun; 58(Pt 6):753-759. PubMed ID: 19429751
[TBL] [Abstract][Full Text] [Related]
46. A retrospective study of the effect of modified multi-drug therapy in Nepali leprosy patients following the development of adverse effects due to dapsone.
Sapkota BR; Shrestha K; Pandey B; Walker SL
Lepr Rev; 2008 Dec; 79(4):425-8. PubMed ID: 19274989
[TBL] [Abstract][Full Text] [Related]
47. Mycobacterium leprae DNA content, cellular and cytokine patterns in skin lesions of leprosy patients undergoing multidrug therapy (MDT).
Flad HD; Richter E; Schlüter C; Duchrow M; Arnoldi J; Hahn M; Graf von Ballestrem W; Alvarenga AE; Gerdes J
Immunobiology; 1994 Oct; 191(4-5):388-94. PubMed ID: 7713552
[TBL] [Abstract][Full Text] [Related]
48. Diagnosis and treatment of leprosy type 1 (reversal) reaction.
Sung SM; Kobayashi TT
Cutis; 2015 Apr; 95(4):222-6. PubMed ID: 25942024
[TBL] [Abstract][Full Text] [Related]
49. A case report of erythroderma in a patient with borderline leprosy on reversal reaction: a result of the exacerbated reaction?
Miyashiro D; Vieira AP; Trindade MAB; Avancini J; Sanches JA; Benard G
BMC Dermatol; 2017 Dec; 17(1):16. PubMed ID: 29262820
[TBL] [Abstract][Full Text] [Related]
50. Long-term evaluation of immune status in leprosy patients undergoing multiple drug therapy.
Vu TT; Hoang TL; Nguyen DQ; Ho ML; Nguyen DH; Le TH; Dang DT; Nguyen QA; Le TP; Tran HK
Int J Lepr Other Mycobact Dis; 1994 Sep; 62(3):365-73. PubMed ID: 7963908
[TBL] [Abstract][Full Text] [Related]
51. Leprosy and its reactional episodes: Serum levels and possible roles of omega-3 and omega-6-derived lipid mediators.
de Macedo CS; de Carvalho FM; Amaral JJ; de Mendonça Ochs S; Assis EF; Sarno EN; Bozza PT; Pessolani MCV
Cytokine; 2018 Dec; 112():87-94. PubMed ID: 30017389
[TBL] [Abstract][Full Text] [Related]
52. [Comparative characterization of the antigenic composition of M. leprae and M. lufu].
Salamatina OS; Diachina MN; Iushchenko AA; Chernousova LN; Kalinina ON; Parshin MP
Probl Tuberk; 2001; (8):49-51. PubMed ID: 11767394
[TBL] [Abstract][Full Text] [Related]
53. Role of TEFFECTOR/MEMORY Cells, TBX21 Gene Expression and T-Cell Homing Receptor on Type 1 Reaction in Borderline Lepromatous Leprosy Patients.
Dos Santos LN; da Silva PH; Alvim IM; Nery JA; Lara FA; Sarno EN; Esquenazi D
PLoS One; 2016; 11(10):e0164543. PubMed ID: 27764137
[TBL] [Abstract][Full Text] [Related]
54. Update on the epidemiology, diagnosis, and treatment of leprosy.
Reibel F; Cambau E; Aubry A
Med Mal Infect; 2015 Sep; 45(9):383-93. PubMed ID: 26428602
[TBL] [Abstract][Full Text] [Related]
55. Nasal mucosa and skin of smear-positive leprosy patients after 24 months of fixed duration MDT: histopathological and microbiological study.
Ebenezer GJ; Job A; Abraham S; Arunthathi S; Rao PS; Job CK
Int J Lepr Other Mycobact Dis; 1999 Sep; 67(3):292-7. PubMed ID: 10575409
[TBL] [Abstract][Full Text] [Related]
56. A longitudinal study of immunologic reactivity in leprosy patients treated with immunotherapy.
Rada E; Ulrich M; Aranzazu N; Santaella C; Gallinoto M; Centeno M; Rodriguez V; Convit J
Int J Lepr Other Mycobact Dis; 1994 Dec; 62(4):552-8. PubMed ID: 7868953
[TBL] [Abstract][Full Text] [Related]
57. Type 1 reactions in leprosy--heterogeneity in T-cell functions related to the background leprosy type.
Laal S; Mishra RS; Nath I
Int J Lepr Other Mycobact Dis; 1987 Sep; 55(3):481-93. PubMed ID: 2958570
[TBL] [Abstract][Full Text] [Related]
58. Changes in cellular response to mycobacterial antigens and cytokine production patterns in leprosy patients during multiple drug therapy.
Trao VT; Huong PL; Thuan AT; Anh DD; Trach DD; Rook GA; Wright EP
Immunology; 1998 Jun; 94(2):197-206. PubMed ID: 9741341
[TBL] [Abstract][Full Text] [Related]
59. The immunobiology of leprosy.
Kaplan G; Cohn ZA
Int Rev Exp Pathol; 1986; 28():45-78. PubMed ID: 3516911
[TBL] [Abstract][Full Text] [Related]
60. Is drug-resistant Mycobacterium leprae a real cause for concern?: First approach to molecular monitoring of multibacillary Colombian patients with and without previous leprosy treatment.
Guerrero MI; Colorado CL; Torres JF; León CI
Biomedica; 2014 Apr; 34 Suppl 1():137-47. PubMed ID: 24968045
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
